Status:

COMPLETED

Performance Evaluation of the truSculpt Radiofrequency Device for Lipolysis of Abdominal Fat

Lead Sponsor:

Cutera Inc.

Conditions:

Body Fat

Eligibility:

All Genders

24-60 years

Phase:

NA

Brief Summary

Clinical Study to Evaluate the Performance the truSculpt Radiofrequency Device for Lipolysis of Abdominal Fat

Detailed Description

A single-center, prospective, non-randomized, open-label study to evaluate the truSculpt Radiofrequency Device for non-invasive fat reduction in abdominal tissue for up to 14 subjects. Measurement wil...

Eligibility Criteria

Inclusion

  • Male or Female, 24 to 60 years of age (inclusive)
  • Fitzpatrick Skin Type I - VI (Appendix 3)
  • Has visible fat bulges or skin laxity in the abdominal region
  • Scheduled to undergo surgery (abdominoplasty).
  • Non-smoking for at least 6 months and willing to refrain from smoking for the duration of the study.
  • Subject must agree to not undergo any other procedure(s) in the abdominal region during the study period.
  • Subject must be able to read, understand and sign the Informed Consent Form.
  • Subject must adhere to the follow-up schedule and study instructions.
  • Subject must adhere to the same diet/ exercise/medication regimen for the entire course of the study.
  • Willing to provide histology samples during the surgery from the intended to be harvested areas.
  • Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant.

Exclusion

  • Participation in a clinical trial of another device or drug in the target area during the study period.
  • Any type of prior cosmetic treatment to the target area within 12 months of study participation e.g., radiofrequency, cryolysis or light-based treatments.
  • Any prior invasive cosmetic surgery to the target area, such as liposuction.
  • Has a pacemaker, internal defibrillator, implantable cardioverter-defibrillator, nerve stimulator implant, cochlear implant or any other electronically, magnetically or mechanically activated implant.
  • Has metal implant(s) within the body, such as surgical clips, plates and screws, intrauterine device (IUD), artificial heart valves or artificial joints.
  • Significant concurrent illness, such as diabetes mellitus, cardiovascular disease, peripheral vascular disease or pertinent neurological disorders.
  • Diagnosed or documented immune system disorders.
  • History of any disease or condition that could impair wound healing.
  • History of diseases stimulated by heat, such as recurrent herpes zoster in the treatment area, unless treatment is conducted following a prophylactic regimen.
  • History of keloid formation, hypertrophic scarring or abnormal/delayed wound healing in the treatment area.
  • Infection, dermatitis, rash or other skin abnormality in the target area.
  • Currently undergoing systemic chemotherapy or radiation treatment for cancer, or history of treatment in the target area within 3 months of study participation.
  • Pregnant or currently breastfeeding.
  • As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Key Trial Info

Start Date :

June 15 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 15 2018

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT03433417

Start Date

June 15 2017

End Date

March 15 2018

Last Update

March 17 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cutera Research Center

Brisbane, California, United States, 94005